FH and congenital thrombotic thrombocytopenic purpura: These anti-FHs then disrupt FH’s ability to protect host cells, leading to the clinical manifestations of the disease such as microangiopathic hemolytic anemia, acute renal failure, and thrombocytopenia (32).